BARD1 and breast carcinoma: We found LoF missense variants in BARD1’s structured domains were enriched in breast cancer cases with an odds ratio of 1.73 (95% CI 1.14 – 2.63) (Fig. 3d) and all LoF missense BARD1 variants were enriched in breast cancer cases with an odds ratio of 1.72 (1.19 – 2.48) (Supplementary Table 1).